Dendritic cell-based immunotherapy for prostate cancer.
Dendritic cells are unique in their ability to stimulate naive T cells. These investigators have developed a prostate cancer vaccine using autologous dendritic cells as a vehicle to present prostate antigens to T cells in vivo.
Tjoa
B A
BA
Pacific Northwest Cancer Foundation, Cancer Research Division, Northwest Hospital, Seattle, WA, USA.
Lodge
P A
PA
Salgaller
M L
ML
Boynton
A L
AL
Murphy
G P
GP
D019496:Cancer Vaccines / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D003713:Dendritic Cells / Q000276:immunology*; D006801:Humans; D007167:Immunotherapy; D008297:Male; D011471:Prostatic Neoplasms / Q000276:immunology / Q000628:therapy*
D019496:Cancer Vaccines